Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Bryant

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Seminars in Pediatric Surgery|February 1, 1992
Postanesthesia recoveryL D Bryant, S F Dierdorf
Molecular Biotherapy|March 1, 1991
Generation of MC-38 adenocarcinoma tumor-specific tumor infiltrating lymphocytes by murine anti-CD3 antibody and recombinant interleukin-2R Lafreniere, K Borkenhagen, L D Bryant
Journal of Surgical Oncology|January 1, 1990
MC-38 adenocarcinoma tumor infiltrating lymphocytes: correlation of cytotoxicity with time of tumor harvest after tumor inoculationR Lafreniere, K Borkenhagen, L D Bryant
Journal of Surgical Oncology|February 1, 1990
In vivo administration of picibanil (OK-432) prior to tumor harvest leads to an enhancement of tumor-infiltrating lymphocyte (TIL) cytotoxicityR Lafreniere, K Borkenhagen, L D Bryant
Public Health|October 11, 2001
Prenatal screening for Down's syndrome: some psychosocial implications of a 'screening for all' policyL D Bryant, J M Green, J Hewison
Cancer Research|May 1, 1989
Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2R Lafreniere, K Borkenhagen, L D Bryant, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2R Kim, R Lafreniere, K Borkenhagen, et al.
Journal of Biological Response Modifiers|June 1, 1989
Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvestR Lafreniere, K Borkenhagen, L D Bryant, et al.
Journal of Biological Response Modifiers|February 1, 1990
Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiationR Lafreniere, K Borkenhagen, L D Bryant, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporinF Sutherland, K Borkenhagen, L Temple, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Seminars in Pediatric Surgery|February 1, 1992
Postanesthesia recoveryL D Bryant, S F Dierdorf
Molecular Biotherapy|March 1, 1991
Generation of MC-38 adenocarcinoma tumor-specific tumor infiltrating lymphocytes by murine anti-CD3 antibody and recombinant interleukin-2R Lafreniere, K Borkenhagen, L D Bryant
Journal of Surgical Oncology|January 1, 1990
MC-38 adenocarcinoma tumor infiltrating lymphocytes: correlation of cytotoxicity with time of tumor harvest after tumor inoculationR Lafreniere, K Borkenhagen, L D Bryant
Journal of Surgical Oncology|February 1, 1990
In vivo administration of picibanil (OK-432) prior to tumor harvest leads to an enhancement of tumor-infiltrating lymphocyte (TIL) cytotoxicityR Lafreniere, K Borkenhagen, L D Bryant
Public Health|October 11, 2001
Prenatal screening for Down's syndrome: some psychosocial implications of a 'screening for all' policyL D Bryant, J M Green, J Hewison
Cancer Research|May 1, 1989
Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2R Lafreniere, K Borkenhagen, L D Bryant, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2R Kim, R Lafreniere, K Borkenhagen, et al.
Journal of Biological Response Modifiers|June 1, 1989
Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvestR Lafreniere, K Borkenhagen, L D Bryant, et al.
Journal of Biological Response Modifiers|February 1, 1990
Synergistic actions of picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiationR Lafreniere, K Borkenhagen, L D Bryant, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporinF Sutherland, K Borkenhagen, L Temple, et al.
Pageof 2